Coramaze Technologies Company Profile

Background

Coramaze Technologies, founded in 2013, is a pioneering medical technology company dedicated to advancing minimally invasive solutions for structural heart diseases. The company's flagship product, Tripair™, is designed to address tricuspid regurgitation (TR), a condition where the tricuspid valve fails to close properly, leading to backward blood flow into the right atrium. Coramaze's mission is to provide accessible, effective, and safe treatments for TR patients worldwide, aiming to improve quality of life and reduce morbidity associated with this condition.

Key Strategic Focus

Coramaze's strategic focus centers on the development and commercialization of Tripair™, a transcatheter tricuspid valve repair system. The device employs an innovative edge-to-spacer design, simplifying the repair process and making it accessible to a broader range of patients. By reducing procedural complexity and enhancing safety, Coramaze aims to position Tripair™ as a leading solution in the treatment of tricuspid regurgitation.

Financials and Funding

As of 2025, Coramaze Technologies has secured approximately $6.5 million in total funding, with a significant Series A round of $5.1 million. The company generates an estimated annual revenue of $3.2 million and employs around 19 individuals.

Pipeline Development

Coramaze has made significant strides in the clinical development of Tripair™:

• First-In-Human Study (Completed in 2024): Conducted in South Africa and Serbia, this study treated 10 patients, demonstrating initial safety and streamlined procedure times, with device deployment averaging below 30 minutes.

• Feasibility Study (2025–2027): The upcoming phase aims to evaluate Tripair™ across Europe, North America, and Japan under a global harmonized feasibility protocol. Compassionate use cases continue for patients lacking alternative treatments.

Technological Platform and Innovation

Tripair™ distinguishes itself through several proprietary technologies and methodologies:

• Edge-to-Spacer Design: This innovative approach simplifies the tricuspid valve repair process, potentially reducing procedural complexity and improving patient outcomes.

• Atraumatic Anchoring: The device is anchored in the right atrium without causing trauma, allowing for full retrievability and intra-procedural efficacy evaluation.

Leadership Team

Coramaze's leadership comprises seasoned professionals with extensive experience in medical technology and structural heart care:

• Jochen Reinöhl, CEO: Brings a strong background in cardiovascular medicine and biomedical engineering, leading the company's strategic direction.

• Neil Moat, Chief Medical Officer: Oversees clinical strategies and medical affairs, ensuring the alignment of product development with clinical needs.

• Mary Edwards, Regulatory: Manages regulatory affairs, ensuring compliance with global medical device regulations.

• Grayston Licht, CTO: Leads technological development and innovation efforts.

• Laurie Hayner, VP Clinical Operations: Oversees clinical trial operations and patient safety.

• Shai Assia, VP R&D: Directs research and development activities.

• Jacob van Dam, Director of Quality Assurance: Ensures product quality and compliance with industry standards.

• Carmel van den Berk, Chief of Staff: Manages internal operations and strategic initiatives.

• Konstantin Winterhalder, Director Finance: Oversees financial planning and management.

Leadership Changes

In May 2025, Coramaze appointed Rob ten Hoedt as Chairman of the Board. Ten Hoedt, formerly Executive Vice President and President of Global Regions at Medtronic, brings extensive experience in medical technology innovation and strategic business growth. His leadership is expected to be instrumental as Coramaze advances Tripair™ from feasibility studies to pivotal trials and commercialization.

Competitor Profile

Market Insights and Dynamics

The market for tricuspid valve repair solutions is expanding, driven by the increasing prevalence of tricuspid regurgitation and the demand for minimally invasive treatment options. Advancements in transcatheter technologies are reshaping the landscape, offering new opportunities for patient care.

Competitor Analysis

Key competitors in the tricuspid valve repair market include:

• Edwards Lifesciences: Offers the PASCAL transcatheter valve repair system, focusing on mitral and tricuspid valve diseases.

• Abbott Laboratories: Develops the TriClip device, a transcatheter tricuspid valve repair system.

• Medtronic: Provides the Intrepid transcatheter valve system, targeting mitral and tricuspid valve conditions.

These companies leverage advanced technologies and extensive clinical experience to address structural heart diseases, contributing to a competitive and innovative market environment.

Strategic Collaborations and Partnerships

Coramaze is supported by renowned international healthcare investors, including MTIP, a Swiss-based growth equity and buyout firm specializing in healthcare investments. MTIP has been a committed partner since 2017, supporting Coramaze's journey from early innovation to breakthroughs in tricuspid regurgitation treatment.

Operational Insights

Coramaze's strategic considerations include:

• Market Positioning: Emphasizing the simplicity, safety, and effectiveness of Tripair™ to differentiate from competitors.

• Clinical Validation: Conducting comprehensive clinical trials to establish efficacy and safety, facilitating regulatory approvals.

• Global Expansion: Targeting key markets in Europe, North America, and Japan to maximize patient reach and commercial success.

Strategic Opportunities and Future Directions

Coramaze's future directions encompass:

• Advancing Clinical Programs: Progressing through feasibility and pivotal trials to demonstrate Tripair™'s clinical benefits.

• Regulatory Approvals: Securing approvals in multiple jurisdictions to enable widespread adoption.

• Commercialization: Implementing strategic marketing and distribution plans to introduce Tripair™ to healthcare providers globally.

• Innovation: Continuing research and development to enhance existing technologies and explore new solutions for structural heart diseases.

Contact Information

• Website: www.coramaze.com

• Tripair™ Information: www.tripairtechnology.com

• LinkedIn: Coramaze Technologies

For further inquiries, please visit the official website or LinkedIn page.